eli lilly retatrutide release date to data on weight loss drug in 2025 Eli Lilly 2023: Crossover appeal
Description
The phase 3 clinical trials are due to finish in May 2026
If you have taken a compound sourced outside of licensed channels and experienced side effects, you are strongly encouraged to report this via the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk
Nat Rev Drug Discov 2012;11:255257 [DOI] [PubMed] [Google Scholar] 30.Forrow S, Campion DM, Herrinton LJ, et al
LeRoith D, Biessels GJ, Braithwaite SS, et al
In clinical studies targeting obesity, particularly in the phase 3 trials based on the SURPASS program, tirzepatide demonstrated outstanding weight reduction benefits, with some patients achieving a weight loss of up to 22.5%
Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes
